{
    "nct_id": "NCT03989414",
    "official_title": "A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)",
    "inclusion_criteria": "â€¢ Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2\n\nFor participants in Cohorts A, B, C, D, E, F, H, I, J, and K the following inclusions will also apply:\n\n* Documented diagnosis of multiple myeloma (MM) and measurable disease\n* Documented disease progression during or after their last antimyeloma regimen\n* Achieved a response (minimal response [MR] or better) to at least 1 prior treatment regimen\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) or clinically significant amyloidosis\n* Known central nervous system (CNS) involvement with myeloma\n* Received immunosuppressive medication within the last 14 days of initiating study treatment\n* Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment\n\nOther protocol-defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}